Pascal Piedbois, MD, PhD joins One2Treat as Chief Medical Officer to advance patient-centric innovation in clinical trial design and market access

One2Treat Belgium United Kingdom United States of America

and join the movement towards patient-centric healthcare. 

About One2Treat: 

One2Treat is a forward-thinking partner for biopharmaceutical companies, dedicated to delivering transformative insights in clinical trial design, analysis, and market access evaluations to support holistic treatment decisions.  

Driven by a commitment to patient-centricity, One2Treat leverages modern statistical methodologies and advanced software solutions to integrate multiple specific efficacy and safety outcomes into a single aggregated measure. This approach allows for the estimation of the Net Treatment Benefit based on patients' preferences, ushering in a new era of personalized healthcare. 

One2Treat's unique solution empowers sponsors to optimize the design of registration trials, by incorporating multiple patient-relevant outcomes in a single primary analysis, resulting in smaller sample sizes and more clinically relevant analyses. This leads to significantly shorter recruitment timelines and improved biopharma R&D productivity. Additionally, One2Treat facilitates market access through comprehensive benefit-risk assessments and patient-centric analyses, aligning with the evolving landscape of healthcare needs. 

As initiatives to incorporate patients' preferences into treatment development continue to gain momentum, the adoption of One2Treat's innovative multi-facet trial designs is poised to become the new gold standard in the industry. 

To learn more about how One2Treat is revolutionizing treatment decisions in clinical research and market access, visit: www.one2treat.com.  

 

View original content:https://www.prnewswire.co.uk/news-releases/pascal-piedbois-md-phd-joins-one2treat-as-chief-medical-officer-to-advance-patient-centric-innovation-in-clinical-trial-design-and-market-access-302192054.html

Anzeige

Wenn du diese Nachrichten liest, haben die Profis längst gehandelt. Wie groß ist dein Informationsrü

An der Börse entscheidet das Timing über Rendite. Wer sich nur auf allgemeine News verlässt, kauft oft dann, wenn die größten Gewinne bereits gemacht sind. Sichere dir jetzt den entscheidenden Vorsprung: Der Börsenbrief 'trading-notes' liefert dir dreimal wöchentlich datengestützte Trading-Empfehlungen direkt ins Postfach. Agiere vor der breiten Masse – 100% kostenlos und fundiert.
Jetzt abonnieren .